Literature DB >> 33251811

Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer.

Pietari Mäkelä1, Mikael Anttinen2, Visa Suomi3, Aida Steiner1, Jani Saunavaara3, Teija Sainio3, Antero Horte2, Pekka Taimen4,5, Peter Boström2, Roberto Blanco Sequeiros1.   

Abstract

BACKGROUND: Magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) is an emerging method for treatment of localized prostate cancer (PCa). TULSA-related subacute MRI findings have not been previously characterized.
PURPOSE: To evaluate acute and subacute MRI findings after TULSA treatment in a treat-and-resect setting.
MATERIAL AND METHODS: Six men with newly diagnosed MRI-visible and biopsy-concordant clinically significant PCa were enrolled and completed the study. Eight lesions classified as PI-RADS 3-5 were focally ablated using TULSA. One- and three-week follow-up MRI scans were performed between TULSA and robot-assisted laparoscopic prostatectomy.
RESULTS: TULSA-related hemorrhage was detected as a subtle T1 hyperintensity and more apparent T2 hypointensity in the MRI. Both prostate volume and non-perfused volume (NPV) markedly increased after TULSA at one week and three weeks after treatment, respectively. Lesion apparent diffusion coefficient values increased one week after treatment and decreased nearing the baseline values at the three-week MRI follow-up.
CONCLUSION: The optimal timing of MRI follow-up seems to be at the earliest at three weeks after treatment, when the post-procedural edema has decreased and the NPV has matured. Diffusion-weighted imaging has little or no added diagnostic value in the subacute setting.

Entities:  

Keywords:  Prostate; ablation procedures; magnetic resonance imaging; primary neoplasms

Mesh:

Year:  2020        PMID: 33251811     DOI: 10.1177/0284185120976931

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  2 in total

1.  The role for MRI-guided transurethral ultrasound ablation in the continuum of prostate cancer care.

Authors:  Joseph J Busch
Journal:  Br J Radiol       Date:  2022-03-01       Impact factor: 3.039

2.  Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naïve patients with suspicious prostate cancer.

Authors:  Amr Nowier; Hesham Mazhar; Rasha Salah; Mohamed Shabayek
Journal:  Arab J Urol       Date:  2022-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.